DMMC Course CANCER BIOLOGY TO CANCER MEDICINE II

Durkan Lecture Theatre, Institute of Molecular Medicine, TCD, St James's Hospital

1045-1130 Friday 8 July 2005
Signal Transduction Pathways as Targets for Cancer Therapeutics
Dr Aideen Long (Dept of Biochemistry, RCSI)

SUGGESTED READING

Deininger M, Buchdunger E, Druker BJ. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood. 2005 Apr 1;105(7):2640-53.

Lockhart C, Berlin JD. The epidermal growth factor receptor as a target for colorectal cancer therapy. Semin. Oncol. 2005 Feb;32(1):52-60.

Cohen MS, Zhang C, Shokat KM, Taunton J. Structural bioinformatics-based design of selective, irreversible kinase inhibitors. Science. 2005 May 27;308(5726):1318-21. (and associated commentaries in same issue).

Mass RD. The HER receptor family: a rich target for therapeutic development. Int J Radiat Oncol Biol Phys. 2004 Mar 1;58(3):932-40.

Newell DR. How to develop a successful cancer drug--molecules to medicines or targets to treatments? Eur J Cancer. 2005 Mar;41(5):676-82.

Ghobrial IM, Witzig TE, Adjei AA. Targeting apoptosis pathways in cancer therapy. CA Cancer J Clin. 2005 May-Jun;55(3):178-94.

Pao W, Miller VA. Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions. J Clin Oncol. 2005 Apr 10;23(11):2556-68. Epub 2005 Mar 14.

Zhang Z, Li M, Rayburn ER, Hill DL, Zhang R, Wang H. Oncogenes as novel targets for cancer therapy (part I): growth factors and protein tyrosine kinases. Am J Pharmacogenomics. 2005;5(3):173-90.

Fang JY, Richardson BC. The MAPK signalling pathways and colorectal cancer. Lancet Oncol. 2005 May;6(5):322-7.

Nicholson KM, Anderson NG. The protein kinase B/Akt signalling pathway in human malignancy. Cell Signal. 2002 May;14(5):381-95.

Viatour P, Merville MP, Bours V, Chariot A. Phosphorylation of NF-kappaB and IkappaB proteins: implications in cancer and inflammation. Trends Biochem Sci. 2005 Jan;30(1):43-52.